LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Apr 27, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called LCI-SAR-BSTS-CTDNA-001, is exploring how well a special test can find small pieces of cancer DNA in the blood of patients with bone or soft tissue sarcoma, which is a type of cancer. The test being studied is called Low Pass Whole Genome Sequencing (LP-WGS). Researchers hope that by detecting this circulating tumor DNA (ctDNA), they can learn more about the cancer and how to treat it effectively.
The trial is open to individuals of all ages, including children, who may have a suspected or confirmed diagnosis of sarcoma. This includes patients with a suspected tumor that doctors believe could be sarcoma, those preparing for surgery on a suspected lipomatous mass, or those already diagnosed with sarcoma, whether or not it has spread. If you choose to participate, you will be asked to give consent and provide some personal health information. This trial is not yet recruiting, so there is time to learn more before deciding to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.
- • 2. All ages allowed
- 3. Suspected or confirmed disease (must meet one of the criteria below):
- • 1. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)
- • OR
- • 2. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery
- • OR
- 3. Confirmed bone or soft tissue sarcoma meeting one of the criteria below:
- • Non-metastatic/Resectable sarcoma with either planned or currently receiving therapy
- • Metastatic or unresectable sarcoma, with planned or currently receiving therapy
- • Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy
- Exclusion Criteria:
- • none
About Wake Forest University Health Sciences
Wake Forest University Health Sciences is a leading academic research institution dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on multidisciplinary collaboration, the organization leverages its extensive expertise in medical research, patient care, and education to develop and evaluate new therapies and interventions. Committed to improving patient outcomes and public health, Wake Forest University Health Sciences fosters a dynamic environment for scientific inquiry, engaging in a wide range of clinical studies that address pressing health challenges. Through its rigorous methodologies and ethical standards, the institution aims to contribute significantly to the medical field and enhance the quality of life for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlotte, North Carolina, United States
Patients applied
Trial Officials
Johann Hsu, MD
Principal Investigator
Wake Forest University Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported